South Africa recorded a congenital syphilis rate of 198 per 100,000 live births in 2023, requiring roughly a 75 percent reduction to meet the World Health Organization impact threshold of 50 cases per 100,000 live births by its 2028 target.
Reaching that goal means bridging deep divides in antenatal care. While a 2019 sentinel survey recorded high syphilis screening coverage of 96.4 percent among women attending antenatal clinics, that metric omits mothers who miss prenatal services entirely. In fact, only 57 percent of mothers tied to reported congenital syphilis cases had documented antenatal care attendance.
The available medical tools to reverse these numbers already exist within the national health system. Standard interventions include routine syphilis screening, point-of-care diagnostics, and effective treatment using benzathine penicillin G. Yet persistent structural hurdles disrupt the prevention cascade long before a baby is born.
Gaps frequently appear after an initial diagnosis. Medical literature documents incomplete treatment courses and inadequate clinical follow-up among expectant mothers. Provider knowledge, under-recognition of active infections, and delays in diagnostic rollout further exacerbate the burden across provincial health facilities.
Regional outcomes vary dramatically across South Africa’s provinces. Notified congenital syphilis rates stretch from 17 cases up to 472 cases per 100,000 live births. These sharp disparities reflect a mix of local epidemiological differences, variable health system performance, and differing intensities in regional disease surveillance rather than uniform failures.
| Country / Milestone | Status Achieved | Year |
|---|---|---|
| Cuba (MTCT Elimination) | Validated for HIV and Syphilis | 2015 |
| Thailand (MTCT Elimination) | Validated for HIV and Syphilis | 2016 |
| Botswana (HIV Path to Elimination) | Gold Tier Status | 2025 |
| Namibia (HIV & Hepatitis B) | Bronze (HIV) / Silver (Hep B) | 2023 |
Neighboring African nations offer contrasting models for strengthening maternal health frameworks. In Zambia, commodity stock-outs of benzathine penicillin G disrupted timely maternal treatment, emphasizing the critical need for reliable supply chains. Meanwhile, the Central African Republic deployed a modified reverse-testing algorithm that successfully reduced unnecessary antibiotic use and hospital stays for exposed newborns.
International milestones show that elimination is achievable through sustained political backing and strong primary healthcare. Botswana secured WHO Gold Tier status on the Path to Elimination of mother-to-child transmission of HIV in 2025, building on its Silver Tier recognition from 2021. Namibia earned Bronze Tier status for HIV in 2023 alongside Silver Tier status for hepatitis B. Globally, Cuba achieved dual validation for eliminating mother-to-child transmission of both HIV and syphilis in 2015, with Thailand following in 2016.
South Africa can draw vital lessons from its own successful HIV prevention mother-to-child transmission programs, which share the same antenatal care platform. Expanding integrated screening through dual point-of-care tests increases efficiency during a single clinic visit.
Syphilis management nonetheless demands distinct clinical protocols compared to HIV. While HIV requires lifelong viral suppression and continuous retention in care, syphilis is fully curable with targeted antibiotic treatment. However, it requires strict adherence to timely dosing, rigorous prevention of re-infection, repeat testing at multiple stages of pregnancy, and prompt partner notification and treatment.
Closing the substantial gap before the 2028 validation deadline requires consistent execution across every stage of the prevention cascade. Strengthening early antenatal engagement, ensuring complete maternal therapies, and upgrading surveillance data systems remain immediate national priorities.
